TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28807367
Drug: Consolidative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidative therapy with weekly Paclitaxel
Study: 24300820
Drug: Glatimer acetate
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glatimer acetate (GA) 20 mg daily for at least 12 months
Study: 24300820
Drug: Interferon‐Β 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐Β 44 mg three times a week
Study: 20422199
Drug: High-proanthocyanidin (PA)
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-proanthocyanidin (PA) red de-alcoholised wine (DAW) (500 mL/die, PA dose = 7 mg/kg)
Study: 20422199
Drug: Low-proanthocyanidin rosé
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-proanthocyanidin rosé de-alcoholised wine (DAW) (500 mL/die, PA dose = 0.45 mg/kg)
Study: 19478258
Drug: Doxycycline, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 200 mg/day for six weeks
Study: 17960402
Drug: Choline-stabilized orthosilicic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 9 months
Study: 9212590
Drug: Interferon-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 2b (one dose administration)
Study: 9212590
Drug: High-dose interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose interferon-alpha 2b treatment (6-month course)
Study: 8491012
Drug: Picotamide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picotamide (300 mg t.i.d.)
Study: 2979683
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg or 800 mg
Study: 26197839
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil (single dose during cardiac catheterisation)
Study: 25473190
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg per day for 2 weeks (2W group)
Study: 25473190
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg per day for 4 weeks (4W group)
Study: 21870906
Drug: Red clover
Normalized name: Red clover
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover isoflavones (80 mg, two daily capsules)
Study: 20367823
Drug: Medication Alliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Alliance training (expert group)
Study: 20367823
Drug: Medication Alliance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Alliance training (novice group)
Study: 10471986
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg daily for 11 days
Study: 8734139
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg (morning dose), increased to 10 mg if clinically effective
Study: 8734139
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg (in three divided doses), increased to 240 mg if clinically effective
Study: 6138935
Drug: Pindolol (nonselective,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (nonselective, 10 mg)
Study: 6138935
Drug: Metoprolol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (beta 1‐receptor selective, 100 mg)
Study: 6138935
Drug: Acebutolol (cardioselective,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (cardioselective, 500 mg)
Study: 30646532
Drug: WSP-MR (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: WSP-MR (two packs a day for a total of 132 g of WSP)
Study: 22486209
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL of water before blood donation
Study: 16369229
Drug: EZE/SIMVA (10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA (10/20 mg)
Study: 16369229
Drug: EZE/SIMVA (10/10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA (10/10, 10/20, or 10/40 mg)
Study: 10488363
Drug: Dexamethasone 24
Normalized name: dexAMETHasone 24 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 24 mg intramuscularly in two divided doses 24 hours apart
Study: 8604599
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel 2 mg intravaginally
Study: 8604599
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel 0.5 mg intracervically
Study: 8604599
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel 1 mg intravaginally
Study: 1757608
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol 17-propionate ointment
Study: 3733281
Drug: Enteric-coated tablet
Normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated tablet
Study: 6623020
Drug: Microcrystalline tablet
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microcrystalline tablet
Study: 6623020
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing enterosoluble granules
Study: 26879693
Drug: Target-controlled noradrenaline
Normalized name: noradrenaline hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-controlled noradrenaline infusion to manipulate blood pressure (BP) during surgery
Study: 23292523
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg salbutamol
Study: 21432607
Drug: Manualized dialectical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized dialectical behavioural therapy (DBT) plus methylphenidate
Study: 21432607
Drug: Manualized dialectical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized dialectical behavioural therapy (DBT) plus placebo
Study: 8864022
Drug: Heparin-coated CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated CPB circuits (Group HC)
Study: 25835231
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C deficiency (biochemical depletion below 11 µmol/L)
Study: 17521930
Drug: Asasantin (Dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asasantin (Dipyridamole 200mg/Aspirin 25mg) twice daily (group I; n=39)
Study: 17521930
Drug: Asasantin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asasantin plus 75 mg Clopidogrel once daily (group II; n=33)
Study: 17521930
Drug: Asasantin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asasantin plus Rheomacrodex (Dextran 40) 100g/L iv; 500 ml (group III; n=30)
Study: 11443224
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg daily for 6 months)
Study: 9531962
Drug: Allergen inhalation
Normalized name: catfish allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen inhalation (very low doses)
Study: 7974930
Drug: Diltiazem (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (calcium channel blocker)
Study: 2524959
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for both dipyridamole and aspirin
Study: 2524959
Drug: Dipyridamole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (75 mg) and aspirin (324 mg)
Study: 2524959
Drug: Dipyridamole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (75 mg) and placebo for aspirin
Study: 30991614
Drug: Early high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early high-dose erythropoietin (EPO)
Study: 28249572
Drug: Ertapenem (de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (de-escalation therapy)
Study: 16889454
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg once daily)
Study: 11485511
Drug: Combined continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined continuous hormone replacement therapy (HRT)
Study: 9926277
Drug: Moxonidine (0.3-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.3-0.4 mg/daily)
Study: 7875640
Drug: Fasting conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting conditions (300 mg oral dose of penticainide)
Study: 7875640
Drug: Fed conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fed conditions (300 mg oral dose of penticainide)
Study: 2460520
Drug: 40% alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% alcohol (100 ml intragastric administration)
Study: 30987664
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/kg/h continuous infusion, reduced to 1 mg/kg/h in postanesthesia care unit)
Study: 26581881
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin pump therapy (open-loop)
Study: 16282436
Drug: GLU+FRUC (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU+FRUC (1.0 g/min of GLU + 0.5 g/min of FRUC)
Study: 16282436
Drug: GLU (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLU (1.5 g/min)
Study: 7854793
Drug: Dextromethorphan 13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 13.5 mg t.d.s.
Study: 7854793
Drug: Dextromethorphan 27
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan 27 mg t.d.s.
Study: 21562412
Drug: Dexamethasone phosphate
Normalized name: Dexamethasone Phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone phosphate (DP) 15 mg
Study: 21562412
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (MPA) 80 mg
Study: 14521705
Drug: 0.005% calcipotriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% calcipotriol ointment applied twice a day
Study: 14521705
Drug: 5% coal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% coal tar ointment applied overnight once daily
Study: 10930152
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose ddI
Study: 9058316
Drug: low‐dose natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: low‐dose natural interferon‐alpha (nIFN alpha) for 6 months
Study: 9058316
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of maintenance chemotherapy (CAP)
Study: 9058316
Drug: no maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: no maintenance therapy (control group)
Study: 8437528
Drug: Intravenous molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous molsidomine (4 mg) on the first day
Study: 8437528
Drug: Oral molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral molsidomine (4 mg) on the first day
Study: 8437528
Drug: Oral molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral molsidomine (4 mg) on the second day
Study: 8437528
Drug: Intravenous molsidomine
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous molsidomine (4 mg) on the second day
Study: 20484968
Drug: Topical antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antioxidant pretreatment for 2 weeks
Study: 10599726
Drug: Corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticotropin-releasing hormone (CRH) infusion (1 microg/kg x h in saline)
Study: 10599726
Drug: CRH infusion
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH infusion
Study: 18159577
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine administration
Study: 1929450
Drug: UFT 400
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 400 mg/day
Study: 1929450
Drug: FT 600
Normalized name: FT-1101
DrugBank: FT-1101 (DB17553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FT 600 mg/day
Study: 29040031
Drug: ATLG (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATLG (20 mg/kg per day on days -3, -2, -1)
Study: 27121596
Drug: Lovaza (3.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza (3.36 g daily for 1 year)
Study: 24172159
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication use (lifetime and 12-month)
Study: 24172159
Drug: Alternative medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alternative medicines
Study: 19137353
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg triamcinolone acetonide (steroid group)
Study: 19137353
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg sodium hyaluronate (hyaluronate group)
Study: 11468606
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic ointment and occlusive patch over the affected eye (n=82)
Study: 11468606
Drug: Topical antibiotic
Normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical antibiotic ointment 4 times a day without an occlusive patch (n=81)
Study: 8149360
Drug: L-tyrosine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tyrosine (10 g/day in four divided doses)
Study: 8149360
Drug: L-tyrosine
Normalized name: L-tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tyrosine
Study: 2907520
Drug: L-bunolol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-bunolol (2 mg)
Study: 28415907
Drug: TPM/oxycodone patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPM/oxycodone patch
Study: 18675742
Drug: Vehicle patch
Normalized name: EXYDERM Transdermal Vehicle Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle patch
Study: 26121805
Drug: High-dose amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amino acid administration (4 ml x kg(‐1) x hr(‐1))
Study: 26121805
Drug: Low-dose amino
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose amino acid administration (2 ml x kg(‐1) x hr(‐1))
Study: 26121805
Drug: No amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No amino acid administration
Study: 23278295
Drug: Home-use irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-use irradiation group using an LED device (420-nm blue light and 660-nm red light for 2.5 min twice daily for 4 weeks)
Study: 19623014
Drug: siplizumab (0.012,
Approvals — FDA: no, EMA: no, PMDA: no
Description: siplizumab (0.012, 0.04, 0.12, or 0.4 mg/kg)
Study: 9041974
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg salbutamol sulfate with 0.5 mg ipratropium bromide
Study: 9041974
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg salbutamol sulfate alone
Study: 7705095
Drug: CVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVR with 30 mcg EE
Study: 7705095
Drug: CVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVR with 65 mcg EE
Study: 7705095
Drug: CVR with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVR with 20 and 30 mcg EE
Study: 7705095
Drug: NA/EE oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA/EE oral contraceptives
Study: 7705095
Drug: EE/gestodene oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/gestodene oral contraceptives
Study: 31792304
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy + anti-HER2
Study: 31792304
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + anti-HER2
Study: 22610153
Drug: FEC-D (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC-D (3 cycles of FEC100 followed by 3 cycles of 100 mg/m(2) docetaxel)
Study: 15572415
Drug: T enanthate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate, 200 mg im every 2 weeks, with placebo pills daily (T-only)
Study: 15572415
Drug: T enanthate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate, 200 mg every 2 weeks, with 5 mg finasteride daily (T + F)
Study: 12477979
Drug: Noncontact normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncontact normothermic wound therapy (NNWT)
Study: 2195517
Drug: One-day antibiotic
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-day antibiotic prophylaxis for major resections
Study: 25908001
Drug: Standard-energy SLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-energy SLT treatment (270°)
Study: 25908001
Drug: Sub-threshold energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-threshold energy SLT treatment (360°)
Study: 12849809
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of rFSH
Study: 12849809
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rFSH
Study: 11163812
Drug: Intramuscular 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular 150 IU rFSH
Study: 8021633
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of alcohol (blood concentration of 96mg/dL)
Study: 22318383
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% tretinoin
Study: 19622887
Drug: BoNT‐A (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A (high-dose)
Study: 19622887
Drug: BoNT‐A (other
Approvals — FDA: no, EMA: no, PMDA: no
Description: BoNT‐A (other doses)
Study: 7807627
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G intramuscularly for 10 days
Study: 7807627
Drug: Benzathin penicillin
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathin penicillin G combined with procaine penicillin G as a single dose intramuscularly
Study: 2692189
Drug: Albendazole, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole, 400 mg (single dose)
Study: 2692189
Drug: Mebendazole, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole, 600 mg (single dose)
Study: 811102
Drug: Controlled-release nitroglycerin
Normalized name: nitroglycerin Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release nitroglycerin (2.6 mg tablets administered three times daily)
Study: 11694668
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional physical therapy at least every other week)
Study: 31454023
Drug: Recombinant zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant zoster vaccine
Study: 2672899
Drug: iv caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv caffeine 10 mg/kg
Study: 1164878
Drug: B vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: B vitamins and anabolic steroid clostebol (Steranabol)
Study: 25638752
Drug: Long-peptides plus
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-peptides plus TLR agonists
Study: 25638752
Drug: Adaptive design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive design for identifying optimal treatment strategy
Study: 24355659
Drug: Full-dose iterative
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose iterative (FDI) image reconstruction
Study: 24355659
Drug: Half-dose iterative
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose iterative (HDI) image reconstruction
Study: 24355659
Drug: Full-dose standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose standard (FDS) image reconstruction
Study: 21945081
Drug: High-dose bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bupivacaine
Study: 19541736
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol (400 microg)
Study: 11730442
Drug: High-dose aptiganel
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aptiganel (5-mg bolus followed by 0.75 mg/h for 12 hours; n = 214)
Study: 11730442
Drug: Low-dose aptiganel
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aptiganel (3-mg bolus followed by 0.5 mg/h for 12 hours; n = 200)
Study: 8081045
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + R (chemotherapy with methotrexate, chlorambucil, vincristine, and cisplatin, given every 3 weeks)
Study: 8081045
Drug: R (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R (radiotherapy only, 50 Gy in the pelvis with a boost by external irradiation of the brachytherapy, cumulative dose of 68 Gy)
Study: 29575526
Drug: JNJ‐42165279 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐42165279 (oral selective FAAH inhibitor)
Study: 26033499
Drug: Locoregional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional therapy (LRT) combined with arsenic trioxide (As2 O3) at 10 mg/d for 4 courses (21 days per course) with a 2-week interval between courses